Jolanda Howe sold $2.6M of MIRM
SVP, GLOBAL CONTROLLER at Mirum Pharmaceuticals, Inc.. 57,606 shares at an average of $44.35, traded Mar 17, 2025, filed Mar 18, 2025.
Score components
- +15RoleOfficer
- +25Trade size$2.6M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-008558, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 15, 2025 | MOption exercise Common Stock10b5-1 | +5,315 | - | - | 9,547 | Mar 18, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,900 | $44.21 | $128k | 6,647 | Mar 18, 2025 |
| Mar 17, 2025 | MOption exercise Common Stock10b5-1 | +52,900 | $2.94 | $156k | 59,547 | Mar 18, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -50,111 | $44.33 | $2.2M | 9,436 | Mar 18, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,789 | $44.75 | $125k | 6,647 | Mar 18, 2025 |
| Mar 17, 2025 | SOpen-market sale Common Stock10b5-1 | -1,806 | $44.36 | $80k | 4,841 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Performance Restricted Stock Unitsderivative10b5-1 | -5,315 | $0.00 | $0 | 2,658 | Mar 18, 2025 |
| Mar 17, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -52,900 | $0.00 | $0 | 0 | Mar 18, 2025 |
Related signals
Other insiders at Mirum Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $978k 9,943 shares | -18% | |
| 38Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $66k 658 shares | -52% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.0M 30,000 shares | -13% | |
| 41Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $728k 9,578 shares | -19% | |
| 53Moderate | Mirum Pharmaceuticals, Inc. | Laura Brege director | $1.3M 17,000 shares | -52% | |
| 54Moderate | Mirum Pharmaceuticals, Inc. | William Fairey director | $155k 3,203 shares | -56% | |
| 44Moderate | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $378k 8,203 shares | -144% | |
| 15Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $107k 2,415 shares | -50% | |
| 15Weak | MIRMbuy Mirum Pharmaceuticals, Inc. | Patrick J Heron director | $24k 549 shares | +0% | |
| 30Weak | MIRMbuy Mirum Pharmaceuticals, Inc. | Patrick J Heron director | $100k 2,298 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.